This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Eosinophilic endomyocardial disease

Authoring team

Eosinophilic endomyocardial disease is characterized by:

  • endomyocardial fibrosis
  • a high incidence at temperate latitudes
  • large mural thrombi
  • eosinophilia with infiltration of organs especially the heart (causing restrictive cardiomyopathy)
  • rapid fatality

This disease is closely related to the African condition of endomyocardial fibrosis (qv).

Treatment measures include:

  • suppression of eosinophilia e.g. prednisolone or hydroxycarbamide (former British Approved Name, hydroxyurea)
  • digoxin
  • diuretics

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.